Most S. Korean Pharmaceutical and Biotech Firms Treat R&D Spending as Intangible Assets

SEOUL, March 14 (Korea Bizwire) — Over half of main domestic pharmaceutical and biotech firms have been found to mark R&D investments down as assets rather than expenses. As this accounting approach could result in on-paper operating profits appearing much higher than in actuality, possibly giving rise to a “profit illusion”, the need for thorough [...]